Government reviews DPCO 2013 to sort implementation issues
NEW DELHI: The government is reviewing the Drug (Prices Control) Order, 2013, to sort out implementation issues and make it more efficient -- both for consumers and the industry."We are discussing...and will keep discussing to see if there are any anomalies in the order and at the same time, we want to make the regulations more clear," sources said.The idea is to make the price control order...
Login or Register to read the full article
NEW DELHI: The government is reviewing the Drug (Prices Control) Order, 2013, to sort out implementation issues and make it more efficient -- both for consumers and the industry.
"We are discussing...and will keep discussing to see if there are any anomalies in the order and at the same time, we want to make the regulations more clear," sources said.
The idea is to make the price control order easy to implement, they added.
The government, according to the sources, has sought inputs on DPCO from all stakeholders, including the industry and the civil society.
Meanwhile, a task force constituted by the Department of Pharmaceuticals has also recommended review of DPCO 2013.
"There is a need to review the implementation of DPCO 2013 to resolve genuine practical problems of implementation. The government may implement a predictable and stable price control mechanism through a consultative approach with the industry," the task force had said in its report submitted last month.
Pointing to the shortage of drug inspectors, the task force had suggested one drug inspector per 50 manufacturing units and one inspector per 200 sales/distribution outlets.
As stipulated under DPCO 2013, the National Pharmaceutical Pricing Authority (NPPA) fixes the ceiling price of essential medicines of schedule-I.
So far, the authority has fixed the ceiling price of 530 formulations from the list. And no one is authorised to sell any scheduled formulation (medicine) to a consumer at a price higher than the one notified by NPPA under the order.
While fixing the ceiling price, 16 per cent margin is allowed for retailers. For non-scheduled formulations, there is no control over the launch price.
In respect of medicines not under price control, manufacturers are allowed to increase the maximum retail price (MRP) by 10 per cent annually.
Meanwhile the NPPA also reviewed the price movements of medicines under DPCO,2013 in the month of january 2015 and found that there was a compliance of the DPCO 2013, from a pricing perspective with respect of 99.4 % of SKUs
"We are discussing...and will keep discussing to see if there are any anomalies in the order and at the same time, we want to make the regulations more clear," sources said.
The idea is to make the price control order easy to implement, they added.
The government, according to the sources, has sought inputs on DPCO from all stakeholders, including the industry and the civil society.
Meanwhile, a task force constituted by the Department of Pharmaceuticals has also recommended review of DPCO 2013.
"There is a need to review the implementation of DPCO 2013 to resolve genuine practical problems of implementation. The government may implement a predictable and stable price control mechanism through a consultative approach with the industry," the task force had said in its report submitted last month.
Pointing to the shortage of drug inspectors, the task force had suggested one drug inspector per 50 manufacturing units and one inspector per 200 sales/distribution outlets.
As stipulated under DPCO 2013, the National Pharmaceutical Pricing Authority (NPPA) fixes the ceiling price of essential medicines of schedule-I.
So far, the authority has fixed the ceiling price of 530 formulations from the list. And no one is authorised to sell any scheduled formulation (medicine) to a consumer at a price higher than the one notified by NPPA under the order.
While fixing the ceiling price, 16 per cent margin is allowed for retailers. For non-scheduled formulations, there is no control over the launch price.
In respect of medicines not under price control, manufacturers are allowed to increase the maximum retail price (MRP) by 10 per cent annually.
Meanwhile the NPPA also reviewed the price movements of medicines under DPCO,2013 in the month of january 2015 and found that there was a compliance of the DPCO 2013, from a pricing perspective with respect of 99.4 % of SKUs
Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .
Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement/treatment or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2024 Minerva Medical Treatment Pvt Ltd